Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/656047


The Europe Biotechnology Sectors : A Company and Industry Analysis (October 2006)


Description: This report updates the previous European biotechnology report, focusing on the markets in France, Germany, Sweden, Switzerland, the Netherlands, and the United Kingdom
Current Environment - Key Points
- The market capitalization of Europe's leading biotech companies increased 3.4% from US$16.6 billion to US$17.2 billion from March 8 to September 19 this year, according to a Mergent analysis
Large-cap biotechs performed well but investors increasingly moved away from small- cap companies
- Mergers and acquisitions between biotech firms or with pharmaceutical firms continued to be an important driver of growth, transformation and value creation
For many large firms, M&A are a response to anticipated patent expiration and gaps in a company's product pipeline; for small firms, they are often an attractive exit strategy
- On September 21, Europe's largest biotech company, Serono (SWX: SEO) was bought by Merck for US$13.3 billion
The cash deal created one of Europe's biggest drug groups, with a combined market value of around US$32 billion
- For the first time, Europe recorded a higher number of biotech IPOs than the US in 2005, according to BioCentury, a biotech industry publication
- From January to August, the region saw the completion of eight biotech IPOs, with US$209.6 million raised in total, according to Mergent

Industry Profile - Key Points
- A report in May by biotechnology industry consultancy, Critical I, found the number of biotech companies in Europe and the US was 2,163 and 1,991 respectively
The report found there were a higher percentage of young companies in Europe compared with the US
- In May, 16 research organizations from 12 European countries joined forces in industrial biotech (white biotech)
The network ERA Industrial Biotech (ERA-IB) will work to harmonize currently fragmented research policies
- European biotech companies face slow growth beyond the startup stage
According to Critical I, the capital available to European biotech companies is about one quarter of that available to US companies, although the number of biotech companies in Europe outstripped the US
- However, in the first half of 2006, there was improved enthusiasm for European biotechs
According to BioCentury, the industry raised more than US$17 billion in the first half of this year and, if the trend continues into the second half, 2006 could surpass 2000 as the best funding period ever for biotech
- The EU and national governments continued to set up new initiatives and make significant investments to encourage the growth of the biotech sectors and address funding problems
This year, the EU approved public funding on research to more than US$69.1 billion through the 7 th Research Framework Program 2007-2013 (FP7)
Market Trends and Outlook - Key Points
- In March, the European Medicines Agency (EMEA) published guidelines on similar biological medicinal products, opening the way for biogenerics in Europe
In April, the European Commission (EC) approved the first biogeneric, Sandoz's Omnitrope
- Several biotech companies in Europe and other parts of the world are actively producing biopharmaceuticals in transgenic animals and plants as they provide a cheap source of protein
In June, the first drug from transgenic animals was approved in Europe
- Europe is stepping closer toward a bio-based economy with the adoption of a Strategy for Biofuels in February and the launch of the Biofuels Technology Platform along with the set up of a Biofuels Task Force in June


Contents: Current Environment
- Sector Overview
- Sector Performance
- Leading Companies
- Mergers, Acquisitions and
Alliances
- Initial Public Offerings
Industry Profile
- Sector Size and Value
- Industry Focus Areas
- Sector Investment
- Government Investment
- Policy and Regulatory
Environment
Market Trends and Outlook
- Biogenerics Race Heats Up in
Europe
- Biopharmaceuticals Produced
in Transgenic Animals and
Plants Show Promise
- Europe Moves Towards a Bio-
based Economy
- Europe Rejects Genetically
Modified Crops
- Market Outlook
Country Profiles
- France
- Germany
- Sweden
- Switzerland
- The Netherlands
- United Kingdom
Currency Conversion Table
The Scope of This Report
Key References
Comparative Data
Reports Coverage




Ordering: Order Online - visit http://www.researchandmarkets.com/reports/656047

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 17/02/2012 00:25:42
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
The Europe Biotechnology Sectors : A Company and Industry Analysis (October 2006)
Web Address:
http://www.researchandmarkets.com/reports/656047
Office Code:
OC8IHINLSNNSS

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €100.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 17/02/2012 00:25:42

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)